Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Insmed’s filings can feel like decoding a clinical study: dozens of pages on nebulizer technology, R&D burn, and FDA timelines hidden in dense legal text. If you have ever wondered, “Where can I find Insmed’s quarterly earnings report 10-Q filing?” or needed real-time alerts on Insmed insider trading Form 4 transactions before the market reacts, you are not alone.
Stock Titan removes that friction. Our AI engine highlights trial-related milestones, breaks down cash runway assumptions, and tags every risk factor so you can understand Insmed SEC documents with AI in minutes, not hours. From the Insmed annual report 10-K simplified to each 8-K material events explained, we stream filings from EDGAR the moment they post and layer in plain-English summaries, key metrics, and historical comparisons.
Use cases include:
- Instant email or SMS alerts on Insmed Form 4 insider transactions real-time to monitor executive stock moves.
- Side-by-side Insmed earnings report filing analysis to track R&D expense versus pipeline progress across quarters.
- Quick look-ups of the latest Insmed proxy statement executive compensation without paging through appendices.
Every filing type is covered—10-K, 10-Q, 8-K, S-3, DEF 14A—complete with AI-powered summaries, red-flag detection, and searchable text. Whether you are modeling milestone payments or gauging launch readiness for ARIKAYCE, our platform surfaces the insights hidden in technical jargon. Save hours, spot trends early, and make confident decisions with comprehensive coverage of Insmed SEC filings explained simply.
Insider Trading Activity Report: Sara Bonstein, Chief Financial Officer of Insmed, executed significant transactions on June 23, 2025, through a pre-planned 10b5-1 trading plan established on March 5, 2025.
Transaction Details:
- Exercised 35,253 stock options at $18.95 per share and 12,636 options at $19.74 per share
- Sold 49,104 shares at weighted average price of $101.71 (range: $101.04-$102.03)
- Sold additional 8,661 shares at weighted average price of $102.15 (range: $102.04-$102.61)
Following these transactions, Bonstein holds 93,536 shares directly, plus remaining stock options including 99,007 at $18.95 strike price and 25,124 at $19.74 strike price. The options vest over four years with 25% vesting on first anniversary and 12.5% every six months thereafter.
Form 144 Notice of Proposed Sale filed by Sara Bonstein of Insmed indicates planned sale of 57,765 shares of common stock with an aggregate market value of $5,877,434 through Merrill Lynch. The sale is scheduled for June 23, 2025, on NASDAQ.
The shares were acquired through multiple stock plan activities between May 2024 and June 2025, with the largest acquisition being 47,889 shares on June 23, 2025. The filing reveals significant recent selling activity by Bonstein in the past 3 months:
- June 10, 2025: 57,766 shares sold for $5,146,210
- May 13-14, 2025: Combined 10,504 shares sold for $708,680
- June 3, 2025: 1,579 shares sold for $112,898
Total shares outstanding: 182,138,923. This planned sale represents approximately 0.03% of total shares outstanding.
Form 144 Notice of Proposed Sale filed by John Drayton Wise, indicating planned sale of 20,000 shares of Insmed common stock through Merrill Lynch, with an aggregate market value of $2,099,400. The securities were acquired through Stock Plan Activity on June 23, 2025.
Recent trading activity by the same insider over the past 3 months includes:
- June 13, 2025: 4,486 shares sold for $439,681
- June 3, 2025: 1,860 shares sold for $132,990
- May 2025: Multiple sales totaling 22,133 shares for approximately $1.49 million
Total outstanding shares: 182,138,923. The proposed sale represents approximately 0.011% of outstanding shares. Transaction scheduled for execution on NASDAQ around June 23, 2025.
Insider Trading Alert: William Lewis, Chair and CEO of Insmed (INSM), executed significant transactions on June 16, 2025, through a pre-planned 10b5-1 trading plan established on September 12, 2024.
Key Transaction Details:
- Exercised 129,805 stock options at $10.85 per share through the Katie Procter Dynasty Trust
- Sold a total of 5,204 shares directly at weighted average prices ranging from $98.51 to $101.39
- Disposed of 129,805 shares indirectly through the Katie Procter Dynasty Trust at prices ranging from $98.50 to $101.23
Post-Transaction Holdings:
- Direct ownership: 303,554 shares
- Indirect ownership: 233,924 shares (Katie Procter Dynasty Trust)
- Additional indirect ownership: 50,500 shares (William Lewis Family Legacy Trust)
Insider Trading Alert: Roger Adsett, Chief Operating Officer of Insmed, executed significant stock sales on June 16, 2025, through a pre-planned 10b5-1 trading arrangement established on March 4, 2025.
Transaction Details:
- First transaction: Sold 6,500 shares at weighted average price of $98.50 (range: $97.93-$98.92)
- Second transaction: Sold 4,186 shares at weighted average price of $99.32 (range: $98.94-$99.83)
- Total shares disposed: 10,686 shares
- Remaining holdings: 130,637 shares held directly
The transactions were executed under a Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations by establishing predetermined trading parameters. All shares are held in direct ownership form.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
What is Insmed Inc's primary focus?
What distinguishes ARIKAYCE from other therapies?
Can you explain what brensocatib is?
How does Insmed leverage technology in its drug development?
What role does innovative delivery technology play at Insmed?
What are the key therapeutic areas that Insmed targets?
How does Insmed maintain its global presence?
What can investors learn about Insmed’s clinical development strategy?
